कनाडा - अंग्रेज़ी - Health Canada

glaxosmithkline inc - colfosceril palmitate - powder for suspension - 108mg - colfosceril palmitate 108mg - miscellaneous therapeutic agents

कनाडा - अंग्रेज़ी - Health Canada

glaxosmithkline inc - colfosceril palmitate - powder for suspension - 108mg - colfosceril palmitate 108mg - miscellaneous therapeutic agents

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - colfosceril palmitate 108mg - powder for intratracheal suspension - 108 mg - active: colfosceril palmitate 108mg

यूनाइटेड किंगडम - अंग्रेज़ी - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - colfosceril palmitate - powder for suspension for endotracheopulmonary instillation - 67.5mg

यूनाइटेड किंगडम - अंग्रेज़ी - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - colfosceril palmitate - powder for suspension for endotracheopulmonary instillation - 108mg

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

abbvie limited - bovine lung lipids 25 mg/ml (total phospholipids); colfosceril palmitate 11 mg/ml - 15.5 mg/ml (disaturated phosphatidylcholine); palmitic acid 1.4 mg/ml - 3.5 mg/ml (free fatty acid); tripalmitin 0.5 mg/ml - 1.75 mg/ml (triglycerides) - intratracheal suspension - 25 mg/ml - active: bovine lung lipids 25 mg/ml (total phospholipids) colfosceril palmitate 11 mg/ml - 15.5 mg/ml (disaturated phosphatidylcholine) palmitic acid 1.4 mg/ml - 3.5 mg/ml (free fatty acid) tripalmitin 0.5 mg/ml - 1.75 mg/ml (triglycerides) excipient: sodium chloride water for injection - survanta is indicated for prevention and treatment ("rescue") of respiratory distress syndrome (rds) (hyaline membrane disease) in premature infants. survanta significantly reduces the incidence of rds, mortality due to rds and air leak complications.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - beractant, quantity: 25 mg/ml - suspension - excipient ingredients: colfosceril palmitate; tripalmitin; palmitic acid; sodium chloride; phosphatidyl choline; water for injections - prevention and treatment ("rescue") of respiratory distress syndrome (rds) (hyaline membrane disease) in premature infants.

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

wellcome (ireland) limited - colfosceril palmitate - pdr+solv/susp/epulminst - 13.5 mg/ml

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - beractant -

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

global medical solutions (nz) limited - perflutren 1.1 mg/ml - solution for injection - 1.1 mg/ml - active: perflutren 1.1 mg/ml excipient: colfosceril palmitate dibasic sodium phosphate monohydrate glycerol sodium dipalmitoylphosphatidate n-(methoxy-peg-5000 carbamoyl)-dipalmitoylphosphatidylethanolamine sodium monobasic sodium phosphate monohydrate propylene glycol sodium chloride water for injection